



## Change in Director's Interest in Securities

**15 October 2014, Melbourne:** Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today advises that the interest in the Company's securities held by Dr G Cauwenbergh has changed through his acquisition of shares purchased on the OTCQB in New York on 10 10 14 at a price of US\$0.085 a share.

Attached for release to the market is an Appendix 3Y Notice (Change of Director's Interest).

### Enquiries

David Segal  
Investor Relations Manager  
Phosphagenics Limited  
+61 3 9565 1119

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333

### About Phosphagenics

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM<sup>®</sup> (Targeted Penetration Matrix). TPM<sup>®</sup> is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

### Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

[www.phosphagenics.com](http://www.phosphagenics.com)  
[www.bioelixia.com](http://www.bioelixia.com)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                |                              |
|----------------|------------------------------|
| Name of entity | <b>PHOSPHAGENICS LIMITED</b> |
| ABN            | <b>32 056 482 403</b>        |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                     |                                    |
|---------------------|------------------------------------|
| Name of Director    | <b>CAUWENBERGH, Gerard (Geert)</b> |
| Date of last notice | <b>30 May 2014 (3Y)</b>            |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |                    |
|---|--------------------|
| Direct or indirect interest   | REFER ANNEXURE "A" |
| Nature of indirect interest<br>(including registered holder)<br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>                     | REFER ANNEXURE "A" |
| Date of change  | REFER ANNEXURE "A" |
| No. of securities held prior to change  | REFER ANNEXURE "A" |
| Class   | REFER ANNEXURE "A" |
| Number acquired   | REFER ANNEXURE "A" |
| Number disposed   | REFER ANNEXURE "A" |
| Value/Consideration<br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>   | REFER ANNEXURE "A" |
| No. of securities held after change   | REFER ANNEXURE "A" |
| Nature of change<br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | REFER ANNEXURE "A" |

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |                    |
|---|--------------------|
| Detail of contract  | REFER ANNEXURE "A" |
| Nature of interest  | REFER ANNEXURE "A" |
| Name of registered holder<br>(if issued securities)   | REFER ANNEXURE "A" |
| Date of change  | REFER ANNEXURE "A" |
| No. and class of securities to which interest related prior to change<br>Note: Details are only required for a contract in relation to which the interest has changed | REFER ANNEXURE "A" |
| Interest acquired   | REFER ANNEXURE "A" |
| Interest disposed   | REFER ANNEXURE "A" |
| Value/Consideration<br>Note: If consideration is non-cash, provide details and an estimated valuation   | REFER ANNEXURE "A" |
| Interest after change   | REFER ANNEXURE "A" |

### Part 3 – +Closed period

|   |                |
|---|----------------|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | NO             |
| If so, was prior written clearance provided to allow the trade to proceed during this period?   | NOT APPLICABLE |
| If prior written clearance was provided, on what date was this provided?  | NOT APPLICABLE |

p\asx\3y gw 15 10 14

---

+ See chapter 19 for defined terms.

**ANNEXURE "A"  
APPENDIX 3Y**

**15 October 2014**

**Schedule of Director's Interest**

**DIRECTOR: CAUWENBERGH, Gerard (Geert)**

|  | <b>PRESENT<br/>APPENDIX 3Y<br/>15 10 14<br/>ASX Code : POH</b> | <b>PREVIOUS<br/>APPENDIX 3Y<br/>30 05 14<br/>ASX Code : POH</b> | <b>CHANGES</b> |
|--|--|---|----------------|
| <b>Director's interest in Phosphagenics Limited shares held in name of:</b>      |  |   |                |
| 1 SELF   | <b>20,000</b>  | Nil   | 20,000         |
| 2 <b>TOTAL DIRECTOR'S INTEREST</b>   | <b>20,000</b>  | Nil   | 20,000         |
| 3 Phosphagenics Limited – Number of Shares on Issue                              | <b>1,261,965,957</b>   | 1,020,465,957   | 241,500,000    |
| 4 <b>TOTAL DIRECTORS INTEREST IN SHARES AS PERCENTAGE</b>                        | <b>0.0016%</b>   | Nil   |                |
| <b>Director's interest in Phosphagenics Limited Non-quoted May 2019 Options:</b> |  |   |                |
| 5 SELF   | <b>1,000,000</b>   | 1,000,000   | Nil            |
| 6 Phosphagenics Limited – Number of May 2019 Non-quoted Options                  | <b>3,000,000</b>   | 3,000,000   | Nil            |
| 7 <b>TOTAL DIRECTORS INTEREST IN NON-QUOTED OPTIONS AS PERCENTAGE</b>            | <b>33.33%</b>  | 33.33%  |                |

**COMMENT:**

Dr Cauwenbergh has an interest in the above Phosphagenics Limited issued securities for the following reasons:

- 1 Self – Dr Cauwenbergh is entitled to the above noted securities being the legal and beneficial holder of the securities registered or to be registered in his name.

**Movements in Entitlements**

**Shares**

|  |                      |
|--|----------------------|
| Balance: 30 05 2014  | Nil shares           |
| Acquired, on the OTCQB in New York on 10 10 14 at a price of US\$0.085 a share | <u>20,000 shares</u> |
| Balance, per Appendix 3Y, 15 10 14   | <u>20,000 shares</u> |

**Non-quoted May 2019 (A\$0.172) Options** No Change

p\asx\3y gc 15 10 14

+ See chapter 19 for defined terms.